Overview

A Study for Adults With Plaque Psoriasis

Status:
Terminated

Trial end date:
2010-08-01

Target enrollment:

Participant gender:

Summary

In this study, we will evaluate clinical activity, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of 5 LY2525623 dosing groups compared to placebo in adults with plaque psoriasis.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Antibodies
Immunoglobulins
Interleukin-23